{"id":{"repo_id":"buffalo","oai_identifier":"oai:ubir.buffalo.edu:10477/78497"},"canonical_url":"https://search.dev.ndltd.org/etd/buffalo/oai:ubir.buffalo.edu:10477/78497","repository":{"repo_id":"buffalo","name":"Buffalo","base_url":"https://ubir.buffalo.edu/oai/request"},"display":{"title":"Porphyrin-Phospholipid Liposomes for Chemophototherapy of Solid Tumors","abstract":"Ph.D.","abstract_html":"Ph.D.","abstract_has_math":false,"creators":["Luo, Dandan"],"institution":"State University of New York at Buffalo","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":["Lovell, Jonathan","Biomedical Engineering"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2018,"date_issued":"2018-10-26T02:54:19Z","date_published":"2018-10-26T02:54:19Z","updated_at":"2026-07-27T19:05:09Z","subjects":["bioengineering","pharmaceutical sciences","pharmacology"],"languages":["eng"],"rights":["Users of works found in University at Buffalo Institutional Repository (UBIR) are responsible for identifying and contacting the copyright owner for permission to reuse. University at Buffalo Libraries do not manage rights for copyright-protected works and cannot assist with permissions.","Copyright retained by author."],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/10477/78497","outbound_label":"Handle","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Lovell, Jonathan","Biomedical Engineering"]},{"key":"dc:creator","label":"Author","values":["Luo, Dandan"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2018-10-26T02:54:19Z","2018","2018-06-04 15:04:51"]},{"key":"dc:publisher","label":"Institution","values":["State University of New York at Buffalo"]},{"key":"dc:type","label":"Dc Type","values":["Text","Dissertation"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["bioengineering","pharmaceutical sciences","pharmacology"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["eng"]},{"key":"dc:rights","label":"Dc Rights","values":["Users of works found in University at Buffalo Institutional Repository (UBIR) are responsible for identifying and contacting the copyright owner for permission to reuse. University at Buffalo Libraries do not manage rights for copyright-protected works and cannot assist with permissions.","Copyright retained by author."]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["http://hdl.handle.net/10477/78497"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Ph.D.","Cancer is a major health care burden in the United States and all over the world. The effort of this thesis focuses on the development of doxorubicin encapsulated porphyrin-phospholipid (Dox-PoP) liposomes for the treatment of solid tumors with special interest on pancreatic cancer. Light-triggered release at the target site of action was designed with the hope of releasing chemotherapeutics only in the tumor thereby to reduce the cytotoxicity to healthy organs and reduce the therapeutic dose.[1] Chapter 1 introduces the concept of chemophototherapy (CPT) for treatment of solid tumors and the rational of combination therapeutics, and reviewed related pre-clinical and clinical studies. [2] Chapter 2 involves the characterization and formulation of long-circulating doxorubicin encapsulated PoP (LC-Dox-PoP) liposomes for cancer treatment.[3] Chapter 3 focuses on the pharmacokinetics and pharmacodynamics of the LC-Dox-PoP liposomes on a patient-derived pancreatic xenograft model.[4] In Chapter 4, the impact of drug-light interval on drug disposition and treatment outcomes on MIA Paca2 Xenografts was assessed.[5] Chapter 5 demonstrates that 64Cu labeled LC-Dox-PoP liposomes can be used for multimodal image-guided CPT.[6] Chapter 6 provides a strategy to accelerate the light triggered release rate and minimize the amount of PoP used by incorporating unsaturated phospholipid such as DOPC.[7] In Chapter 7, positive-charged, unsaturated lipid was incorporated into PoP liposome for use in vessel targeted CPT and strong vascular photodynamic therapy (PDT) effect was observed. [8] Chapter 8 involves the study of HPPH liposomes which exhibited increased leakiness with higher drug-lipid loading ratio.[9] This study also demonstrated that the majority of enhanced tumor drug accumulation is attributed to PDT-induced vascular permeabilization. Chapter 9 presents a brief discussion and some future directions of CPT and LC-Dox-PoP liposomes."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dc:title","label":"Title","values":["Porphyrin-Phospholipid Liposomes for Chemophototherapy of Solid Tumors"]}]}],"canonical_facts":{"dc:contributor":["Lovell, Jonathan","Biomedical Engineering"],"dc:creator":["Luo, Dandan"],"dc:date":["2018-10-26T02:54:19Z","2018","2018-06-04 15:04:51"],"dc:description":["Ph.D.","Cancer is a major health care burden in the United States and all over the world. The effort of this thesis focuses on the development of doxorubicin encapsulated porphyrin-phospholipid (Dox-PoP) liposomes for the treatment of solid tumors with special interest on pancreatic cancer. Light-triggered release at the target site of action was designed with the hope of releasing chemotherapeutics only in the tumor thereby to reduce the cytotoxicity to healthy organs and reduce the therapeutic dose.[1] Chapter 1 introduces the concept of chemophototherapy (CPT) for treatment of solid tumors and the rational of combination therapeutics, and reviewed related pre-clinical and clinical studies. [2] Chapter 2 involves the characterization and formulation of long-circulating doxorubicin encapsulated PoP (LC-Dox-PoP) liposomes for cancer treatment.[3] Chapter 3 focuses on the pharmacokinetics and pharmacodynamics of the LC-Dox-PoP liposomes on a patient-derived pancreatic xenograft model.[4] In Chapter 4, the impact of drug-light interval on drug disposition and treatment outcomes on MIA Paca2 Xenografts was assessed.[5] Chapter 5 demonstrates that 64Cu labeled LC-Dox-PoP liposomes can be used for multimodal image-guided CPT.[6] Chapter 6 provides a strategy to accelerate the light triggered release rate and minimize the amount of PoP used by incorporating unsaturated phospholipid such as DOPC.[7] In Chapter 7, positive-charged, unsaturated lipid was incorporated into PoP liposome for use in vessel targeted CPT and strong vascular photodynamic therapy (PDT) effect was observed. [8] Chapter 8 involves the study of HPPH liposomes which exhibited increased leakiness with higher drug-lipid loading ratio.[9] This study also demonstrated that the majority of enhanced tumor drug accumulation is attributed to PDT-induced vascular permeabilization. Chapter 9 presents a brief discussion and some future directions of CPT and LC-Dox-PoP liposomes."],"dc:format":["application/pdf"],"dc:identifier":["http://hdl.handle.net/10477/78497"],"dc:language":["eng"],"dc:publisher":["State University of New York at Buffalo"],"dc:rights":["Users of works found in University at Buffalo Institutional Repository (UBIR) are responsible for identifying and contacting the copyright owner for permission to reuse. University at Buffalo Libraries do not manage rights for copyright-protected works and cannot assist with permissions.","Copyright retained by author."],"dc:subject":["bioengineering","pharmaceutical sciences","pharmacology"],"dc:title":["Porphyrin-Phospholipid Liposomes for Chemophototherapy of Solid Tumors"],"dc:type":["Text","Dissertation"]},"updated_at":"2026-07-27T19:05:09Z"}